LRIG1 is a pleiotropic androgen receptor-regulated feedback tumor suppressor in prostate cancer

Journal: Nature Communications

Published: 2019-12-02

DOI: 10.1038/s41467-019-13532-4

Affiliations: 8

Authors: 22

Go to article
Institutions Share
Department of Epigenetics and Molecular Carcinogenesis, MD Anderson Cancer Center, United States of America (USA) 0.52
Department of Pharmacology and Therapeutics, RPCI, United States of America (USA) 0.38
Duke Department of Pathology, United States of America (USA) 0.05
Tongji Hospital (TJH), HUST, China 0.02
State Key Laboratory Breeding Base of Basic Science of Stomatology, WHU, China 0.01
MOE Key Laboratory of Oral Biomedicine, WHU, China 0.01
Institute for Regenerative Medicine at East Hospital, Tongji University, China 0.01
Research Center for Translational Medicine at East Hospital, Tongji University, China 0.01

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER